GlassScriptPhysician profile
Robert A Reiss
NPI 1609876341
$3,795.68
in general payments reported to CMS, 2019-2025
25 companies · $1,242 in 2025
The $1,242 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2021: $170 · 2022: $197 · 2023: $1,085 · 2024: $958 · 2025: $1,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,233 · Education: $50.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,233.47 |
| Education | $50.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $878.63 | 2021-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $474.39 | 2025 | |
| Travere Therapeutics, INC. | $334.51 | 2023-2025 | Filspari |
| Calliditas Therapeutics US INC. | $271.57 | 2022-2025 | Tarpeyo |
| Amgen INC. | $263.68 | 2022-2025 | Tavneos, Krystexxa |
| Ardelyx, INC. | $181.01 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Otsuka America Pharmaceutical, INC. | $174.58 | 2023-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $166.78 | 2024 | Acthar |
| Akebia Therapeutics INC | $162.33 | 2019-2025 | Vafseo |
| Nxstage Medical, INC. | $133.61 | 2025 | Nxstage System One |
| Abbott Laboratories | $108.66 | 2021 | |
| Baxter Healthcare | $103.59 | 2019 | |
| Fresenius USA Marketing, INC. | $76.83 | 2019-2024 | Velphoro |
| Vifor Pharma, INC. | $72.66 | 2022 | |
| Aurinia Pharma U.S., INC. | $51.36 | 2024 | Lupkynis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.58 | 2025 | Jardiance |
| Lilly USA, LLC | $44.93 | 2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $40.94 | 2023-2024 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $37.38 | 2022-2024 | |
| Horizon Therapeutics Plc | $35.15 | 2023 | Krystexxa |
| Linus Health, INC. | $31.34 | 2023 | |
| Abiomed | $30.00 | 2025 | |
| Novo Nordisk INC | $29.32 | 2025 | Rivfloza, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $26.16 | 2022 | |
| Cormedix INC. | $18.69 | 2025 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Reiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.